Objective: High-sensitivity C-reactive protein (CRP), a marker of systemic inflammation, is a powerful predictor of cardiovascular risk. We hypothesised that n-3 fatty acids reduce underlying inflammatory processes and consequently CRP concentrations in healthy middle-aged subjects. Design: Placebo-controlled, double-blind study. Subjects: A total of 43 men and 41 postmenopausal women aged 50-70 y. Before and after intervention, we measured serum CRP concentrations with an enzyme immunoassay. Interventions: Capsules with either 3.5 g/day fish oil (1.5 g/day n-3 fatty acids) or placebo for 12 weeks. Results: The median CRP change in the fish oil group did not significantly differ from that in the placebo group (0.01 vs À0.17 mg/l, P ¼ 0.057).
Introduction
Blood markers of low-grade inflammation are emerging as risk indicators for coronary heart disease (Danesh et al, 2000) . High-sensitivity C-reactive protein (CRP) is a marker of systemic inflammation produced by the liver and a powerful predictor of cardiovascular risk in healthy populations (Ridker et al, 2002; Yeh & Willerson, 2003) . Dietary effects on markers of inflammatory processes have hardly been studied and are not yet established (de-Maat et al, 2000; Sierksma et al, 2002) . N-3 fatty acids are suggested to have anti-inflammatory effects; they appear to reduce the production of inflammatory cytokines associated with several chronic diseases, such as rheumatoid arthritis (Kremer, 2000) and inflammatory bowel disease (Belluzzi, 2002) . We hypothesised that n-3 fatty acids from fish reduce underlying inflammatory processes and in this way CRP concentrations.
Subjects and methods
The primary purpose of this placebo-controlled, doubleblind study was to study effects of n-3 fatty acids on markers of arrhythmia; details have been published elsewhere (Geelen et al, 2002) . A total of 43 men and 41 postmenopausal women aged 50-70 y were randomised within strata of habitual fish consumption, diastolic blood pressure, and sex (Geelen et al, 2003) to receive either a daily dose of 3.5 g fish oil or placebo (Loders Croklaan, Wormerveer, the Netherlands) for 12 weeks as indistinguishable capsules. The fish oil provided approximately 700 mg eicosapentae-noic acid (C20:5n-3, EPA), 560 mg docosahexaenoic acid (C22:6n-3, DHA), and 260 mg of other n-3 fatty acids per day. The placebo was high-oleic-acid sunflower oil (C18:1n-9). Subjects were instructed to maintain their usual diet and lifestyle. In diaries, they reported illness, irregular medication use, and other deviations from their usual lifestyle. Intakes of energy and nutrients were estimated by 24-h dietary recalls. Subjects abstained from fish, seafood, or (additional) fish oil supplements from 4 weeks before and during the study. We measured CRP concentrations and n-3 fatty acids in cholesteryl esters in nonfasting blood samples at baseline and end (Zock et al, 1997) . High-sensitivity CRP concentrations were measured with an enzyme immunoassay (de Maat et al, 1996) . CRP standard serum was used for calibration. The intra-assay variation was 5.8% for low (B0.5 mg/l), 2.7% for intermediate (B2 mg/l), and 4.8% for high (B10 mg/l) CRP values. Because of the skewed distribution of CRP values, we present values as medians and interquartile ranges. Differences in response between the fish oil and the placebo group were analysed using the MannWhitney U-test.
Results
Three subjects had CRP concentrations greater than 10 mg/l at one of the two blood collections and reported flu-like symptoms in their diary preceding that blood collection. We excluded them from the data reported here (Yeh and Willerson, 2003) . Inclusion of the outliers did not materially affect the results. Compliance was supported by a change in the proportion of EPA (C20:5n-3) in serum cholesteryl esters of 282% (from 0.7670.29 to 2.9170.67 g/100 g fatty acids) in the fish oil group and of À6% in the placebo group. Background dietary intake was similar in the two treatment groups. During the study, the fish oil group consumed 0.5% of the energy as n-3 fatty acids, 6% as linoleic acid (C18:2n-6), and 6% as alcohol. In the placebo group, the corresponding figures were 0.4%, 5% and 5%, respectively. The habitual fish intake was 8.477.9 g n-3 fatty acids per month in the fish oil group and 8.777.3 g n-3 fatty acids per month in the placebo group.
The median CRP change in the fish oil group (0.01 mg/l) was not significantly different (P ¼ 0.057) from that in the placebo group (À0.17 mg/l) ( Figure 1, Table 1 ).
Discussion
Supplementation with 1. 5 g of n-3 fatty acids per day did not lower CRP concentrations in healthy middle-aged subjects. The results would point towards an increase rather than a decrease of CRP with n-3 fatty acids relative to placebo. Other studies on fish oil and inflammation provide conflicting results. In healthy volunteers, increasing fish oil intake suppressed the in vitro synthesis of interleukin-2, interleukin1b, interleukin-1a, and tumor necrosis factor-a (Endres et al, 1989 (Endres et al, , 1993 . However, placebo-controlled studies found that fish oil does not affect ex vivo cytokine production (Blok et al, 1997) or the functional activity of neutrophils, monocytes, or lymphocytes in healthy humans (Kew et al, 2003) . Few studies investigated effects of n-3 fatty acids on CRP. Pischon et al (2003) performed a cross-sectional analysis in 859 men and women. They reported a modest inverse relation between intake of EPA þ DHA and CRP levels. In obese individuals, 4 g/day fish oil for 6 weeks did not decrease CRP (Chan et al, 2002) . A recent study in healthy young subjects (mean age 38 y) with lower baseline CRP concentrations (median 0.78 mg/l) than in our study reported no effect of n-3 fatty acids on CRP (Madsen et al, 2003) . Our study shows that n-3 fatty acids also do not affect CRP in a middle-aged population that might be more prone to low-grade systemic inflammations (median CRP concentration 1.24 mg/l). We cannot exclude that n-3 fatty acids affect other inflammatory markers or CRP at higher concentrations during n-3 fatty acids and C-reactive protein A Geelen et al systemic inflammation. However, the currently available data -including ours-do not support that beneficial effects on CRP are involved in a mechanism explaining the protective effect on heart disease risk of n-3 fatty acids as present in fish.
